Suppr超能文献

口服异维A酸后外用他扎罗汀维持治疗痤疮:综述与病例报告

Maintenance Acne Treatment with Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports.

作者信息

Miranti Shanna M

机构信息

Ms. Miranti is with Riverchase Dermatology and Cosmetic Surgery in Naples, Florida.

出版信息

J Clin Aesthet Dermatol. 2024 Nov-Dec;17(11-12 Suppl 1):S14-S17.

Abstract

Acne is a chronic dermatologic disorder that can require long-term treatment. To prevent recurrence after oral treatment for severe acne, topical maintenance treatment is recommended; however, there is little guidance or research on maintenance regimens. This article briefly summarizes literature on oral isotretinoin and topical retinoids and presents a case series of patients who received tazarotene 0.045% lotion as maintenance following oral isotretinoin. While oral isotretinoin is efficacious, relapse/remission rates range from 0 to 69 percent depending on the definition of relapse/remission, dose, and duration of treatment/follow-up. In addition, oral isotretinoin is a known teratogen, and long-term use (>2 courses of 15-20 weeks) is not recommended. Topical treatments such as retinoids are recommended for maintenance, and some studies support that adapalene and tazarotene provide a benefit. Tazarotene 0.045% lotion is efficacious and safe, with demonstrated reductions in acne, acne-induced post-inflammatory hyperpigmentation, and melasma. In my clinic, patients with severe recalcitrant acne received once-daily oral isotretinoin for at least 20 weeks until clinically clear. On the day of last isotretinoin dose, once-daily topical tazarotene 0.045% lotion was initiated for 6 to 12 months. A total of 12 patients completed 24.3 (6.7) weeks (mean [standard deviation]) of isotretinoin (cumulative dose: 184.6 [75.1] mg/kg) and 13.0 (6.7) months of post-isotretinoin tazarotene 0.045%. No patients relapsed and all showed subjective visual improvements in acne-related scarring with topical tazarotene. None discontinued tazarotene due to adverse events. These case reports show that tazarotene 0.045% lotion may be an effective and safe treatment to prevent relapse after initial oral isotretinoin treatment.

摘要

痤疮是一种慢性皮肤病,可能需要长期治疗。为预防重度痤疮口服治疗后的复发,建议进行局部维持治疗;然而,关于维持治疗方案的指导和研究很少。本文简要总结了关于口服异维A酸和局部维甲酸的文献,并介绍了一系列患者的病例,这些患者在口服异维A酸后接受0.045%他扎罗汀洗剂作为维持治疗。虽然口服异维A酸有效,但复发/缓解率根据复发/缓解的定义、剂量以及治疗/随访时间的不同,在0%至69%之间。此外,口服异维A酸是一种已知的致畸剂,不建议长期使用(超过2个疗程,每个疗程15 - 20周)。推荐使用维甲酸等局部治疗进行维持治疗,一些研究支持阿达帕林和他扎罗汀有治疗效果。0.045%他扎罗汀洗剂有效且安全,已证明可减少痤疮、痤疮引起的炎症后色素沉着和黄褐斑。在我的诊所,重度难治性痤疮患者每天口服异维A酸至少20周,直至临床症状消退。在最后一次口服异维A酸的当天,开始每天一次外用0.045%他扎罗汀洗剂,持续6至12个月。共有12名患者完成了24.3(6.7)周(均值[标准差])的异维A酸治疗(累积剂量:184.6 [75.1] mg/kg)以及异维A酸治疗后13.0(6.7)个月的0.045%他扎罗汀治疗。没有患者复发,所有患者在使用他扎罗汀局部治疗后,痤疮相关瘢痕在主观视觉上均有改善。没有患者因不良事件而停用他扎罗汀。这些病例报告表明,0.045%他扎罗汀洗剂可能是预防初始口服异维A酸治疗后复发的一种有效且安全的治疗方法。

相似文献

3
Minocycline for acne vulgaris: efficacy and safety.
Cochrane Database Syst Rev. 2003(1):CD002086. doi: 10.1002/14651858.CD002086.
4
Interventions for infantile haemangiomas of the skin.
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD006545. doi: 10.1002/14651858.CD006545.pub3.
5
Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Health Technol Assess. 2006 Nov;10(46):1-233, i-iv. doi: 10.3310/hta10460.
6
Ivermectin and permethrin for treating scabies.
Cochrane Database Syst Rev. 2018 Apr 2;4(4):CD012994. doi: 10.1002/14651858.CD012994.
7
Minocycline for acne vulgaris: efficacy and safety.
Cochrane Database Syst Rev. 2000(2):CD002086. doi: 10.1002/14651858.CD002086.
8
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Cochrane Database Syst Rev. 2017 Jan 13;1(1):CD010369. doi: 10.1002/14651858.CD010369.pub2.
9
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000544. doi: 10.1002/14651858.CD000544.pub3.
10
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Cochrane Database Syst Rev. 2016 May 9;2016(5):CD000544. doi: 10.1002/14651858.CD000544.pub4.

本文引用的文献

1
Guidelines of care for the management of acne vulgaris.
J Am Acad Dermatol. 2024 May;90(5):1006.e1-1006.e30. doi: 10.1016/j.jaad.2023.12.017. Epub 2024 Jan 30.
2
Topical Treatments for Melasma and Post-inflammatory Hyperpigmentation.
J Drugs Dermatol. 2023 Nov 1;22(11):1118-1123. doi: 10.36849/JDD.7754.
3
Topical Treatments for Photoaged Skin.
J Drugs Dermatol. 2023 Sep 1;22(9):867-873. doi: 10.36849/JDD.7753.
4
Acne Vulgaris Relapse in Sudanese Patients Treated with Oral Isotretinoin: Rate and Predictive Factors.
J Multidiscip Healthc. 2023 Mar 30;16:839-849. doi: 10.2147/JMDH.S405509. eCollection 2023.
8
Dermatology: how to manage acne vulgaris.
Drugs Context. 2021 Oct 11;10. doi: 10.7573/dic.2021-8-6. eCollection 2021.
10
50 Years of Topical Retinoids for Acne: Evolution of Treatment.
Am J Clin Dermatol. 2021 May;22(3):315-327. doi: 10.1007/s40257-021-00594-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验